Recent research have converged on the overlap of GLP-1|GIP|GCGR agonist therapies and dopaminergic neurotransmission. While GLP agonists are commonly employed for treating type 2 diabetes, their potential impacts on motivation circuits, specifically mediated by dopaminergic pathways, are attracting significant focus. This report details a concis… Read More